Lunit said Tuesday that it would present one of the latest studies using its AI biomarker platform, Lunit Scope, at the Society for Immunotherapy of Cancer 2024 (SITC 2024) in Houston, Texas, from Nov. 6 to 10.

Lunit will present a study on AI-enabled immuno-oncology treatment response prediction in patients with various cancer types, including rare cancers. The SITC’s Academy of Immuno-Oncology Nominating Committee recognized the research's importance and selected it for a Rapid Oral Presentation.

The Rapid Oral Presentation is an oral session offered by SITC to the best abstracts selected based on scientific merit and innovation. Its focus is on quickly sharing research results and clinical implications in a more condensed format.

“AI is breaking new ground in 'personalized cancer care' by precisely interpreting complex tumor microenvironments that were previously difficult to analyze with the naked eye,” Lunit CEO Suh Beom-seok said. "This research opens the door to more effective treatment options, especially for patients with rare cancers.”